MS
IPSC icon

Maven Securities’s Century Therapeutics IPSC Stock Holding History

Maven Securities’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-48,483
Closed -$1.45M – 1158
2021
Q2 		$1.45M Buy
+48,483
New +$1.23M 0.06% 315

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Maven Securities's IPSC Position: Q3 2021 in Review

Maven Securities sold out of Century Therapeutics (IPSC) in Q3 2021, closing a stake of 48,483 shares — an estimated $1.45M sold.

Maven Securities first reported a position in IPSC in Q2 2021 and held it in 1 quarter. The position peaked at $1.45M in Q2 2021. 49 funds tracked by Wall St. Rank hold IPSC as of Q3 2021.

  • Maven Securities reported no remaining Century Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 48,483 Century Therapeutics shares in Q3 2021, an estimated $1.45M.
  • Maven Securities first reported a position in Century Therapeutics in Q2 2021 and held it in 1 quarter.
  • Maven Securities's Century Therapeutics position peaked at $1.45M in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.